Back to top

Ocrevus™ (ocrelizumab) for RRMS - Federal Government approves PBS listing

1 February 2018

The Federal Government today announced the listing of Ocrevus (ocrelizumab) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).

In 2017, Ocrevus was registered for use in Australia by the Therapeutic Goods Administration (TGA), for the treatment of patients with RRMS, to delay the progression of physical disability and to reduce the frequency of relapse.  Ocrevus ™ was also registered for use in people living with Primary Progressive MS (PPMS), to delay the progression of physical disability.

Ocrevus was then recommended for listing on the PBS for RRMS by the Pharmaceutical Benefits Advisory Committee (PBAC), to make this new MS medication affordable. But this approval by the PBAC is always subject to final approval by the Australian Government Cabinet.

Following today’s government announcement, those eligible for Ocrevus for RRMS will pay a maximum of $39.50 per script, or $6.40 for concessional patients.  

For MS Australia (MSA), a key focus is on people living with MS, being able to effectively manage their condition, and we stand alongside them in seeing this announcement as a positive step.  

At this stage, the PBAC has not recommended listing Ocrevus ™ on the PBS for Primary progressive multiple sclerosis (PPMS); MSA will continue to pursue PBS listing for this medication for people with PPMS, as a matter of priority and will keep you posted on progress.

As no two people with MS experience the condition in the same way, it’s important that people with MS discuss any potential treatments with their neurologist or MS nurse.

Like all drugs, Ocrevus has some side effects and is not suited to all people with MS. More details on this and other important information is outlined in the MSA treatment sheet (link below).

Please consult your neurologist to see if Ocrevus is the right treatment for you. Decisions about treatments, taking into consideration the potential benefits and side effects for your individual circumstance, should be made in careful consultation with your healthcare team.

As the national advocacy organisation for people living with MS, MS Australia continues to work with our partner organisations to ensure the MS community and their healthcare teams, have access to the broadest range of affordable treatments as possible.